secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001628280-26-011080
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corcept Q4 revenue $202.1M, FY2025 $761.4M; guides FY2026 revenue $900M-$1B
---------------------------------------------------------------------------

- Q4 2025 revenue $202.1M (vs $181.9M Q4 2024); full-year revenue $761.4M (vs $675.0M in 2024).
- Diluted EPS: Q4 $0.20, FY2025 $0.82 (vs Q4 2024 $0.26, FY2024 $1.23). Net income declined due to stock repurchases and operational costs.
- Cash and investments $532.4M at Dec 31, 2025; spent $245.9M on stock repurchases in 2025.
- FY2026 revenue guidance $900M-$1B; expects continued Cushing's syndrome business growth.
- PDUFA date July 11, 2026 for relacorilant NDA in platinum-resistant ovarian cancer; FDA engaged after CRL for Cushing's NDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000162828026011080/0001628280-26-011080-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000162828026011080/cort-20260224.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-011080

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer